Chronic Liver Disease
121
13
15
57
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
13 trials with published results (11%)
Research Maturity
57 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.6%
8 terminated out of 121 trials
87.7%
+1.2% vs benchmark
15%
18 trials in Phase 3/4
23%
13 of 57 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 57 completed trials
Clinical Trials (121)
EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
Copper Supplementation in Cirrhosis
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
An Observational Study of Patients With Chronic Liver Disease
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in MASLD Related Compensated Advanced Chronic Liver Disease.
To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.
Measuring Patient Reported Needs in Outpatient Liver Disease Management
Endoscopic Ultrasound Shear Wave Elastography Study
Comparison of the Acute Effects of Chest Physiotherapy Methods Applied in Different Positions in Preterm Newborns
hepatomiR cACLD Study
VIATORR Device Registry
Comparing Portal Vein Assessment by Intraoperative Doppler and Transesophageal Echocardiography
Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases
The SHUNT-V Study for Varices
D-SOLVE Cohorts (Cohort a and B)
Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant
Albumin Modifications as Early Biomarkers of Chronic Liver Diseases